Investors & Media
Overview
We are a privately held pharmaceutical company focused on the development and commercialization of Tuclar, our oral testosterone (T) replacement product that is in Phase III clinical testing. If approved by the Food and Drug Administration (FDA), Tuclar will be a first-in-class T-replacement therapy in the United States as the first oral formulation of a T prodrug, namely, T undecanoate (TU).
Based on our clinical results to date, we believe Tuclar may restore circulating T to normal levels and overcome the safety challenges, such as liver toxicity, historically associated with oral T-replacement therapies.
Our investors are Thomas, McNerney & Partners, L.P., H.I.G. BioVentures and ProQuest Investments.